BMS050 (Lung Cancer)
What is the Purpose of this Study?
This study has 2 parts: a screening period and a study dosing period.
If you join this study, during the screening period you will:
- Have blood draws
- Visit the clinic for various tests to see if you're eligible for the dosing period
If you're eligible for the dosing period, you will:
- Have blood draws
- Have imaging scans (CT and MRI)
- Receive nivolumab and chemotherapy with or without the study drug, BMS986012, followed by more chemotherapy
-- All drugs used in this study are given by injection into a vein (IV) every 3 weeks.
You will be randomly assigned (fair chance) to receive the study drug or a placebo (an inactive substance).
Treatments will continue as long as you are benefitting.
If you join this study, during the screening period you will:
- Have blood draws
- Visit the clinic for various tests to see if you're eligible for the dosing period
If you're eligible for the dosing period, you will:
- Have blood draws
- Have imaging scans (CT and MRI)
- Receive nivolumab and chemotherapy with or without the study drug, BMS986012, followed by more chemotherapy
-- All drugs used in this study are given by injection into a vein (IV) every 3 weeks.
You will be randomly assigned (fair chance) to receive the study drug or a placebo (an inactive substance).
Treatments will continue as long as you are benefitting.
What is the Condition Being Studied?
Small Cell Lung Cancer (SCLC)
Who Can Participate in this Study?
Adults age 18 or older who:
- Are diagnosed with extensive SCLC
For more information about who can be in this study, please contact the study team at (919) 681-4768.
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to see how an experimental drug called BMS986012 works in your body and against your cancer when it's given in combination with an immunotherapy drug and chemotherapy.
Study Details
Full Title
A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with
Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer. BMS CA001-050
Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer. BMS CA001-050
Principal Investigator
Protocol Number
IRB:
PRO00107286
NCT:
NCT04702880
ClinicalTrials.gov
View on ClinicalTrials.gov